Subscribe to RSS
DOI: 10.1007/BF01623895
© Georg Thieme Verlag KG Stuttgart · New York
Genetic polymorphism of methylenetetrahydrofolate reductase (MTHFR) and coronary artery disease
Presented in part at the 41st Annual World Congress, International College of Angiology, Sapporo, Japan, July 1999.Publication History
Publication Date:
24 April 2011 (online)
Abstract
A high plasma homocysteine concentration is a risk factor for atherosclerotic disease and venous thrombosis. Homocysteine levels are influenced by folic acid, vitamin B 6 and vitamin B 12, as well as by hereditary factors. A common genetic variant of the methylenetetrahydrofolate reductase (MTHFR) gene CC 677 T) is associated with thermolability of the MTHFR enzyme and elevated plasma homocysteine concentration, especially in those with low folic acid concentration. The prevalence of point mutation (nucleotide 677 C → T) in MTHFR was measured in patients with coronary artery disease (CAD) who all underwent coronary artery bypass surgery (62 cases; age 64.0 ± 9.5 years), and was compared with, age-matched control subjects. In patients with coronary artery disease (CAD), we investigated the prevalence of point mutation (nucleotide 677 C → T) in MTHFR in comparison with control subjects. Heterozygous (C/T) prevalence for the 677 C → T mutation in the MTHFR was higher in patients with CAD than in control subjects (P < 0.05). The prevalence of homozygosity (C/C) for wild-type MTHFR was lower in patients with CAD in comparison with control subjects (P < 0.05).